Education
About Us
Working with TipRanks
Follow Us
ValiRx PLC (GB:VAL)
LSE:VAL
VAL Stock Chart & Stats
0.40 p
>-0.01 p(-0.67%)
At close: 4:00 PM EST
0.40 p
>-0.01 p(-0.67%)
Day’s Range― - ―
52-Week Range0.22 p - 0.88 p
Previous CloseN/A
Volume1.58M
Average Volume (3M)1.10M
Market Cap
£2.27M
Enterprise Value-402.36K
Total Cash (Recent Filing)£1.56M
Total Debt (Recent Filing)£11.86K
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Jun 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding742,801,100
10 Day Avg. Volume510,641
30 Day Avg. Volume1,099,814
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.24
Price to Sales (P/S)20.52
P/FCF Ratio-0.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Equity PositionA high equity ratio provides a durable capital buffer to support long development cycles and absorb setbacks. That equity strength reduces near-term insolvency risk, making the company a more stable partner for collaborators and better positioned to pursue clinical milestones before raising costly capital.
Low Financial LeverageMinimal debt lowers fixed financial obligations and interest burden, preserving cash flexibility critical for R&D-intensive biotech. This structural conservatism reduces default risk during trial delays and gives management optionality to choose strategic funding via partnerships or targeted financings.
Diversified Revenue Model PotentialMultiple non-dilutive and partnership-based revenue avenues create durable funding options as programs progress. Licensing and milestone structures can monetize assets without full commercialization risk, lowering dependency on equity markets and aligning incentives with larger pharma partners over time.
Bears Say
Persistent UnprofitabilitySustained net losses and negative margins undermine internal capital generation, forcing repeated external funding. Over the medium term this can dilute shareholders, constrain strategic freedom, and pressure management to prioritize short-term cash raises over optimal long-term R&D decisions.
Negative Free Cash Flow And Funding RelianceNegative free cash flow and dependence on financing create structural funding risk. Access to capital can be episodic and costly, which may delay trials or force unfavorable deals. Over months this raises execution risk for clinical timelines and diminishes runway if milestones slip.
Negative Gross And Operating MarginsNegative gross and operating margins indicate the business cannot cover direct and overhead costs from current revenues. With a very low revenue base, scaling is inefficient and fixed costs weigh heavily, making it harder to reach sustainable margins without successful asset commercialization or cost restructuring.
ValiRx plc News
VAL FAQ
What was ValiRx PLC’s price range in the past 12 months?
ValiRx PLC lowest share price was 0.22 p and its highest was 0.88 p in the past 12 months.
What is ValiRx PLC’s market cap?
ValiRx PLC’s market cap is £2.27M.
When is ValiRx PLC’s upcoming earnings report date?
ValiRx PLC’s upcoming earnings report date is Jun 10, 2026 which is in 91 days.
How were ValiRx PLC’s earnings last quarter?
Currently, no data Available
Is ValiRx PLC overvalued?
According to Wall Street analysts ValiRx PLC’s price is currently Overvalued.
Does ValiRx PLC pay dividends?
ValiRx PLC does not currently pay dividends.
What is ValiRx PLC’s EPS estimate?
ValiRx PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx PLC have?
ValiRx PLC has 742,801,100 shares outstanding.
What happened to ValiRx PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ValiRx PLC?
Currently, no hedge funds are holding shares in GB:VAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ValiRx PLC
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.
Technical Analysis
Evgen Pharma
―
ImmuPharma
―
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Options Prices
Currently, No data available
---